Spelling suggestions: "subject:"nonalcoholic hepatitis"" "subject:"nonalcoholics hepatitis""
11 |
DEVELOPMENT OF AN RNAi THERAPEUTIC STRATEGY AGAINST NON-ALCOHOLIC STEATOHEPATITIS (NASH)Yenilmez, Batuhan O. 01 September 2021 (has links)
Nonalcoholic steatohepatitis (NASH) is a severe liver disorder characterized by triglyceride accumulation, severe inflammation, and fibrosis. With the recent increase in prevalence, NASH is now the leading cause of liver transplantation, with no approved therapeutics available. Despite years of research, the exact molecular mechanism of NASH progression is not well understood, but fat accumulation is believed to be the primary driver of the disease. Therefore, diacylglycerol O-acyltransferase 2 (DGAT2), a key enzyme in triglyceride synthesis, has been explored as a NASH target. RNAi-based therapeutics is revolutionizing the treatment of liver diseases, with recent chemical advances supporting long term gene silencing with single subcutaneous administration. Here we identified a hyper-functional, fully chemically stabilized GalNAc conjugated siRNA targeting DGAT2 (Dgat2-1473) that upon injection elicits up to three months of DGAT2 silencing (>80-90%, p<0.0001) in wild-type and NSG-PiZ “humanized” mice.
Using an obesity-driven mouse model of NASH (ob/ob-GAN), Dgat2-1473 administration prevents and reverses triglyceride accumulation (> 50%, p:0.0008), resulting in significant improvement of the fatty liver phenotype. However, surprisingly, the reduction in liver fat didn’t translate into a similar impact on inflammation and fibrosis. Thus, while Dgat2-1473 is a practical, long-lasting silencing agent for potential therapeutic attenuation of liver steatosis, combinatorial targeting of a second pathway may be necessary for therapeutic efficacy against NASH.
|
12 |
Untersuchungen zur therapeutischen Anwendung mesenchymaler Stammzellen bei chronischen Lebererkrankungen am Beispiel der Nicht-alkoholischen SteatohepatitisWinkler, Sandra 25 November 2014 (has links)
Die Nicht-alkoholische Steatohepatitis (NASH), gehörig zu der Gruppe der chronischen Lebererkrankungen als eine schwere Form der Nicht-alkoholischen Fettleber-erkrankungen (NAFLD), nimmt in ihrer Prävalenz ständig zu. Gründe dafür sind u.a. eine gesteigerte Nahrungsaufnahme sowie Veränderungen der Nahrungszusammen-setzung. Es kommt zur Ausbildung einer Steatose, die sich unter Mitwirkung verschie-dener Einflussfaktoren zur Steatohepatitis weiterentwickeln kann, wobei die Pathoge-nese noch nicht genau verstanden ist. Die Nicht-alkoholische Steatohepatitis geht oft einher mit Insulinresistenz und starkem Übergewicht. Die Folgen für die Leber sind Funktionseinschränkungen und –verlust, hervorgerufen durch eine massive Akkumula-tion von Triglyzeriden in den Hepatozyten, Entzündungsprozesse sowie einem fibro-tischen Umbau der Leber. Im fortgeschritten Stadium wird eine Lebertransplantation unausweichlich, die jedoch aufgrund des zunehmenden Mangels an Spenderorganen oft nicht möglich ist. Eine Alternative bietet die Transplantation mesenchymaler Stammzellen (MSC). MSC können in vitro in leberzellähnliche Zellen differenziert wer-den und weisen dabei essentielle hepatozytäre Eigenschaften auf, wodurch sie als möglicher Ersatz bzw. als Überbrückungstherapie bis zur Lebertransplantation in Frage kommen. Die vorliegende Arbeit beschäftigte sich mit dieser Fragestellung. Dazu wur-de ein Tiermodell der NASH mittels Methionin-Cholin-defizienter Diät (MCD-Diät) etab-liert und die Transplantation von hepatozytär differenzierten MSC durchgeführt. An-hand spezifischer zellulärer und biochemischer Marker der NASH konnte die Wirkung des Zelltransplantats auf die Empfängerleber analysiert werden. Es hat sich gezeigt, dass die MSC einen anti-inflammatorischen, anti-fibrotischen und pro-proliferativen Einfluss auf das Empfängerparenchym hatten und somit zur Verbesserung der Symptomatik der NASH beitrugen.
|
13 |
Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discriminationBlank, Valentin, Petroff, David, Beer, Sebastian, Böhling, Albrecht, Heni, Maria, Berg, Thomas, Bausback, Yvonne, Dietrich, Arne, Tönjes, Anke, Hollenbach, Marcus, Blüher, Matthias, Keim, Volker, Wiegand, Johannes, Karlas, Thomas 14 February 2022 (has links)
Patients with type 2 diabetes (T2D) are at risk for non-alcoholic fatty liver disease (NAFLD) and associated complications. This study evaluated the performance of international (EASL-EASD-EASO) and national (DGVS) guidelines for NAFLD risk stratification. Patients with T2D prospectively underwent ultrasound, liver stiffness measurement (LSM) and serum-based fibrosis markers. Guideline-based risk classification and referral rates for different screening approaches were compared and the diagnostic properties of simplified algorithms, genetic markers and a new NASH surrogate (FAST score) were evaluated. NAFLD risk was present in 184 of 204 screened patients (age 64.2 ± 10.7 years; BMI 32.6 ± 7.6 kg/m2). EASL-EASD-EASO recommended specialist referral for 60–77% depending on the fibrosis score used, only 6% were classified as low risk. The DGVS algorithm required LSM for 76%; 25% were referred for specialised care. The sensitivities of the diagnostic pathways were 47–96%. A simplified referral strategy revealed a sensitivity/specificity of 46/88% for fibrosis risk. Application of the FAST score reduced the referral rate to 35%. This study (a) underlines the high prevalence of fibrosis risk in T2D, (b) demonstrates very high referral rates for in-depth hepatological work-up, and (c) indicates that simpler referral algorithms may produce comparably good results and could facilitate NAFLD screening.
|
14 |
The role of caspase-1 in liver and adipose tissue during metabolic dysregulation in mouse models on NASHDixon, Laura J. 07 March 2013 (has links)
No description available.
|
15 |
Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver DiseaseBoehlig, Albrecht, Gerhardt, Florian, Petroff, David, van Boemmel, Florian, Berg, Thomas, Blank, Valentin, Karlas, Thomas, Wiegand, Johannes 02 June 2023 (has links)
Patient-reported outcomes are important in nonalcoholic fatty liver disease (NAFLD). Pruritus is of special interest for evolving therapies with farnesoid X receptor (FXR) agonists. The aim of this study was to investigate the prevalence of pruritus in a real-life NAFLD cohort and analyze associations with anxiety and depression. Pruritus was assessed using a visual analogue- (VAS) and 5-D itch-scale (5-D). Anxiety and depression were evaluated by Beck’s-Depression-Inventory (BDI) and the Hospital Anxiety and Depression Scale (HADS-A, HADS-D). An optimal logistic regression model was found with a stepwise procedure to investigate variables associated with pruritus. In total, 123 NAFLD patients were recruited. VAS and 5-D were highly correlated (Spearman’s correlation coefficient 0.89). Moderate/severe pruritus was reported in 19% (VAS) and 21% (5-D) of patients. Anxiety and depression were present in 12% and 4% (HADS-A and HADS-D, respectively) and 12% (BDI) of cases. There was a significant association between VAS and BDI (p = 0.019). The final multivariate model for 5-D included diabetes mellitus (OR 4.51; p = 0.01), BDI (OR 5.98; p = 0.024), and HADS-A (OR 7.75; p = 0.011). One-fifth of NAFLD patients reported moderate or severe pruritus. 5-D was significantly associated with diabetes mellitus, depression, and anxiety. These findings should be tested in larger populations and considered in candidates for treatment with FXR agonists.
|
16 |
Mitochondrial Transfer by Human Mesenchymal Stromal Cells Ameliorates Hepatocyte Lipid Load in a Mouse Model of NASHHsu, Mei-Ju, Karkossa, Isabel, Schäfer, Ingo, Christ, Madlen, Kühne, Hagen, Schubert, Kristin, Rolle-Kampczyk, Ulrike E., Kalkhof, Stefan, Nickel, Sandra, Seibel, Peter, von Bergen, Martin, Christ, Bruno 13 April 2023 (has links)
Mesenchymal stromal cell (MSC) transplantation ameliorated hepatic lipid load; tissue inflammation; and fibrosis in rodent animal models of non-alcoholic steatohepatitis (NASH) by as yet largely unknown mechanism(s). In a mouse model of NASH; we transplanted bone marrow-derived MSCs into the livers; which were analyzed one week thereafter. Combined metabolomic and proteomic data were applied to weighted gene correlation network analysis (WGCNA) and subsequent identification of key drivers. Livers were analyzed histologically and biochemically. The mechanisms of MSC action on hepatocyte lipid accumulation were studied in co-cultures of hepatocytes and MSCs by quantitative image analysis and immunocytochemistry. WGCNA and key driver analysis revealed that NASH caused the impairment of central carbon; amino acid; and lipid metabolism associated with mitochondrial and peroxisomal dysfunction; which was reversed by MSC treatment. MSC improved hepatic lipid metabolism and tissue homeostasis. In co-cultures of hepatocytes and MSCs; the decrease of lipid load was associated with the transfer of mitochondria from the MSCs to the hepatocytes via tunneling nanotubes (TNTs). Hence; MSCs may ameliorate lipid load and tissue perturbance by the donation of mitochondria to the hepatocytes. Thereby; they may provide oxidative capacity for lipid breakdown and thus promote recovery from NASH-induced metabolic impairment and tissue injury.
|
17 |
Livsstilsförändringar vid fetma : En litteraturstudie som undersöker livsstilsförändringar samt hur täta kontakter påverkar följsamhetenAldén, Erik January 2018 (has links)
Background: Obesity has become one of our times most endemic disease on a global scale and changes to lifestyle is the most cost-effective way to treat patients, when the cost for healthcare related treatment is staggeringly high for obesity and sequela diseases NAFLD, diabetes typ 2, dyslipidaemia and metabolic syndrome.The problem with this remedy is that it requires work and dedication. But changes require hard work, and in this patient group- low compliance, weight gain after treatment, dropping out of programs and small desire to change are the most common problems. Motivational studies report that readiness in obese patients is low and the best way to help patients to move forward is by motivational conversations. The obesity sequela disease NAFLD is an asymptomatic disease it displays no symptoms until very late stages. Therefore it’s a problem to get patients make the patient understand his illness and the seriousness of it. Aim: This literature work was aimed at investigating compliance in lifestyle changes in obese subject and to see if close contact with healthcare staff affected the achieved results. Method: In this literature study, the databases Pubmed, Science Direct, Medline and Sportdiscus were used to find information. Article inclusion criteria were that the articles were not older than 10 years and were in English. Result: Frequent and regular contacts between participants and professional staff provided good results both with regard to weight loss, biochemical response, and the participants' willingness to change. Also it shows that return visits at least every three months will improve weight loss if the participant is motivated to implement a change to lifestyle. Conclusion: Overall, this literature study shows the difficulties with lifestyle changes in people with obesity and sequela NAFLD. Close contacts of the patients with healthcare staff has proven to have a positive impact on treatment compliance, but there are other lifestyle difficulties in these patient groups which hamper compliance.
|
18 |
Effets hépatoprotecteurs de PPARα : rôle physiopathologique et bases moléculaires des activités PPARα dans l'inflammation aiguë et la stéatohépatite non alcoolique / Hepatoprotective effects of PPARα : molecular basis and pathophysiological role of PPARα in acute inflammation and non-alcoholic steatohepatitisPawlak, Michal 17 December 2013 (has links)
La stéatohépatite non alcoolique (NASH) est une maladie du foie à évolution clinique grave, dont la prévalence est en constante progression. La stéatohépatite non alcoolique est caractérisée par un dépôt excessif de lipides dans les hépatocytes (stéatose) associé à une inflammation chronique, au contraire de la stéatose hépatique (NAFLD), manifestation initiale mais bénigne d'un dérèglement métabolique. Le NASH augmente le risque de progression vers la fibrose, la cirrhose et le carcinome hépatocellulaire et ne peut être soigné que par une greffe hépatique. Le risque de développer un diabète de type est aussi significativement augmenté chez les patients atteints de NASH. PPAR⍺ est un récepteur nucléaire connu pour réguler l'utilisation des acides gras dans le foie et réprimer les voies de signalisation pro-inflammatoires. [...]Nous avons conçu mutant de PPAR⍺ dont l'activité de liaison à l'ADN est abolie. La comparaison de ses activités transcriptionnelles in vitro avec le PPAR⍺ non muté démontre que les activités de contrôle du métabolisme sont abolies pour ce mutant, alors que les activités anti-inflammatoires restent intactes. [...] Dans cette étude, nous montrons donc pour la première fois que PPAR⍺ inhibe la progression de la stéatose vers le NASH et la fibrose par un mécanisme anti-inflammatoire direct, indépendant de son effet sur le métabolisme lipidique hépatique. / Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent liver condition characterized by excessive lipid deposition in the hepatocytes steatohepatitis (NASH) is hallamarked by chronic inflammation. NASH markedly increases the risk of progression towards liver fibrosis, cirrhosis ans hepatocellular carcinoma. The nuclear peroxisome proliferator-activated receptor alpha (PPAR⍺) regulates hepatic fatty acid utilization and represses pro-inflammatory signaling pathways. [...]Liver-specific expression of wild type or DNA binding-deficient PPAR⍺ in acute and chronic models of inflammation demonstrated that PPAR's anti-inflammatory, but not metabolic activities, result from DNA binding-independent mechanisms in vivo. We futher show that PPAR⍺ inhits the transition from steatosis toward NASH and fibrosis through a direct, anti-inflammatory mechanism independent of its effetc on hepatic lipid metabolism.
|
19 |
Rôles du stress du réticulum endoplasmique et de Bax Inhibitor-1 dans les complications hépatiques liées à l’obésité / The roles of endoplasmic reticulum stress and Bax inhibitor-1 in non-alcoholic fatty liver diseaseLebeaupin, Cynthia 26 April 2018 (has links)
La pandémie de l'obésité entraine une augmentation de la prévalence des maladies chroniques du foie ou stéatopathies métaboliques (NAFLD). Le spectre des NAFLD va de la stéatose caractérisée par une accumulation de lipides dans le foie à la stéatohépatite (NASH) associant une inflammation, de la mort hépatocytaire et de la fibrose. Lors de l'obésité, l'élévation de signaux de dangers métaboliques perturbe les fonctions du réticulum endoplasmique (RE) essentielles pour l’homéostasie cellulaire. Les perturbations sont transmises par 3 senseurs : IRE1α, ATF6 et PERK pour activer une réponse adaptative. Si ce stress est sévère ou devient chronique, la cellule enclenchera une réponse terminale apoptotique. La protéine Bax Inhibitor-1 (BI-1) pourrait jouer un rôle hépatoprotecteur en inhibant l’hyperactivation de la voie de signalisation IRE1α.En combinant des études chez l’homme et dans des modèles animaux, l’objectif de cette étude était de mieux caractériser l'activation chronique du stress du RE dans les NAFLD. Ce travail a émis l’hypothèse qu’une déficience en BI-1 entrainerait l’activation soutenue de la voie IRE1α qui serait responsable de la transition de la stéatose à la NASH. Cette étude s'intéresse au dialogue potentiel entre le stress du RE et l’activation de l'inflammasome NLRP3, qui induit la sécrétion des cytokines pro-inflammatoires (IL-1β, IL-18) grâce aux caspases pro-inflammatoires (caspase-1, caspase-4/11). L’utilisation d’un inhibiteur global du stress du RE ou des inhibiteurs pharmacologiques spécifiques à la voie IRE1α améliorerait les caractéristiques pathophysiologiques de la NASH et pourrait ouvrir de nouvelles perspectives thérapeutiques. / Due to the obesity pandemic, the last decades have been marked by a constantly increasing prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD). NAFLD covers a spectrum of hepatic disorders ranging from steatosis, characterized by the ectopic accumulation of lipids in the liver, to steatohepatitis (NASH), featuring inflammation, hepatocellular death and fibrosis. During obesity, an increase in metabolic danger signals leads to disrupted endoplasmic reticulum (ER) function, essential for cellular homeostasis. The resulting ER stress activates a signaling network involving three sensors: IRE1α, ATF6 and PERK to enforce adaptive programs. If this stress is severe or becomes chronic, the cell will trigger a terminal apoptotic response. The protein Bax Inhibitor-1 (BI-1), as a negative endogenous regulator of the IRE1α signaling pathway in the liver, may play a hepatoprotective role.By combining data from obese patients with liver complications and experimental approaches in mice, this thesis aimed to better characterize the chronic activation of ER stress in NAFLD pathogenesis. This work also emitted the hypothesis that a deficiency in BI-1 leads to unrestrained IRE1α signaling that may be responsible for the steatosis to NASH transition. This study further investigated the potential dialogue between ER stress and the activation the NLRP3 inflammasome, which induces the secretion of pro-inflammatory cytokines (IL-1β, IL-18) by activating pro-inflammatory caspases (caspase-1, caspase-4/11). The administration of a broad spectrum ER stress inhibitor or specific inhibitors of IRE1α improved the pathophysiological features of NASH and may open novel therapeutic perspectives.
|
20 |
Exploiting Sexual Dimorphism in Liver Disease: Targeting Sex Hormone Signaling to Treat Non-Alcoholic Fatty Liver Disease and Hepatocellular CarcinomaHelms, Timothy H. January 2021 (has links)
No description available.
|
Page generated in 0.0832 seconds